Fed­er­al ap­peals court heav­i­ly ques­tions FDA, Dan­co lawyers in abor­tion drug case

The fate of the abor­tion drug mifepri­s­tone is still up in the air in the US af­ter three fed­er­al ap­peals court judges heav­i­ly ques­tioned the gov­ern­ment and Dan­co Lab­o­ra­to­ries over whether the FDA fol­lowed the prop­er process when it loos­ened ac­cess to the drug.

Mifepri­s­tone was first ap­proved by the FDA in 2000, and the reg­u­la­tor made a num­ber of changes in 2016 that broad­ened ac­cess to the prog­es­terone block­er, in­clud­ing al­low­ing it to be shipped in the mail and pre­scribed by a wider range of health­care pro­fes­sion­als, not just physi­cians.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN